Insulet Corporation
Innovative diabetes medical devices
- B2C
About Insulet Corporation
Develops and manufactures wearable insulin delivery systems, simplifying life for people with diabetes. Products provide continuous, tubeless insulin delivery without injections.
Key facts
- Industry
- Medical Equipment Manufacturing
- Company size
- 5,001–10,000 employees
- Headquarters
- Acton, Massachusetts, United States
- Founded
- 2000
- Revenue
- $2.7BFY2025, publicly reported
- Website
- insulet.com
Jobs at Insulet Corporation
- Sr Manager, Talent Acquisition - Global Ops - Hybrid (Acton, MA)
- Graduate Co-op, Supplier Engineering - Project Management Excellence: January - June 2027 (Onsite)
- Senior Director, Global Operations Digital Transformation (Hybrid - Acton, MA)
- Senior Test Manager (Performance Testing, Salesforce & Integrations)
- Production Line Manager (12 Hour Weekend Night Shift - Onsite)
- Global HEMA New Offerings Manager (Hybrid: Acton, MA or San Diego, CA)
- Global HEMA New Offerings Manager (Hybrid: Acton, MA or San Diego, CA)
- Co-op, Supplier Engineering - Project Management Excellence: January - June 2027 (Onsite)
Insulet Corporation in the news
- Important Notice to Long-Term Shareholders of Beta Bionics,
Insulet Corporation faces an investigation by Grabar Law Office concerning defective manufacturing controls, leading to voluntary medical device corrections for its Omnipod products due to potential insulin under-delivery.
- Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Insulet Corporation will report its third-quarter 2026 financial results on November 4, 2026, with a conference call scheduled for the same day.
- Insulet (NASDAQ:PODD) Offers Affordable Growth With Strong Fundamentals
Insulet Corporation demonstrates strong growth and profitability, with a reasonable valuation compared to industry peers, despite some concerns regarding financial health and potential growth deceleration.
- Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says
Insulet anticipates increased competition from new market entrants in 2027 and 2028, according to Oppenheimer.
- Insulet Corp. stock underperforms Monday when compared to competitors
Insulet Corp. stock underperformed on Monday compared to its competitors.
Insulet Corporation at a glance
Insulet Corporation is a B2C company in the Medical Equipment Manufacturing industry, headquartered in Acton, Massachusetts, United States.
Insulet Corporation was founded in 2000.
Insulet Corporation has 5,001–10,000 employees.
Insulet Corporation's revenue is $2.7B (FY2025, publicly reported).
Insulet Corporation is hiring: 8 recent open roles, including Sr Manager, Talent Acquisition - Global Ops - Hybrid (Acton, MA), Graduate Co-op, Supplier Engineering - Project Management Excellence: January - June 2027 (Onsite), Senior Director, Global Operations Digital Transformation (Hybrid - Acton, MA).
Selling to companies like Insulet Corporation?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies